Back to mobile site
Get it on Google Play

Kyowa Kirin begins phase 2 trial of ziftomenib in Japan for AML

April 24, 2026 8:00 AM EDT Send to a Friend
Kyowa Kirin Co., Ltd. (TSE: 4151) and Kura Oncology, Inc. (NASDAQ: KURA) announced the first patient has been dosed in ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login